Verici Dx (LSE:VRCI) COGS-to-Revenue : 0.00 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Verici Dx COGS-to-Revenue?

Verici Dx's Cost of Goods Sold for the six months ended in Jun. 2024 was £0.00 Mil. Its Revenue for the six months ended in Jun. 2024 was £2.62 Mil.

Verici Dx's COGS to Revenue for the six months ended in Jun. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Verici Dx's Gross Margin % for the six months ended in Jun. 2024 was N/A%.

Verici Dx COGS-to-Revenue Historical Data

The historical data trend for Verici Dx's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx COGS-to-Revenue Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
COGS-to-Revenue	Get a 7-Day Free Trial			-	-	0.13	-	-

Verici Dx COGS-to-Revenue Calculation

Verici Dx's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.8
	=	0.00

Verici Dx's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	2.624
	=	0.00

Verici Dx (LSE:VRCI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Verici Dx's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 2.624
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Verici Dx COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Verici Dx's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

63V:Germany

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines